

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK1, IC50: 108 nM ULK2, IC50: 711 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | EN460 is a small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) and interacts selectively (IC50=1.9 μM) with the reduced, active form of ERO1α and prevents its reoxidation. |
| Concentration | Treated Time | Description | References | |
| HeLa cells | 20 μM | 2 hours | Evaluate the inhibitory effect of EN460 and its analogs on VEGF secretion, results showed that I2 and I3 effectively inhibited VEGF secretion | Cell Death Dis. 2025 Feb 17;16(1):105 |
| MM1.S cells | IC50 = 14.74 μM | 72 hours | Inhibited cell proliferation | Bioorg Med Chem. 2019 Apr 15;27(8):1479-1488 |
| U266 cells | 25 μM | 18 hours | Induced apoptosis | Bioorg Med Chem. 2019 Apr 15;27(8):1479-1488 |
| ventricular myocytes (VMs) | 20 µmol/L | 5 minutes | EN460 inhibited Ero1α activity, reduced SR oxidation in TAB VMs, and improved Ca2+ handling | Circ Res. 2022 Mar 4;130(5):711-724 |
| SJSA | 8 μM | 24 hours | Inhibiting ERO1 activity, reducing ROS production, thereby alleviating CYT997-induced apoptosis | J Exp Clin Cancer Res. 2019 Jan 31;38(1):44 |
| 143B | 8 μM | 24 hours | Inhibiting ERO1 activity, reducing ROS production, thereby alleviating CYT997-induced apoptosis | J Exp Clin Cancer Res. 2019 Jan 31;38(1):44 |
| MiaPaca-2 cells | 5 μM, 10 μM, 25 μM | 24 hours | Inhibited migration and invasion of PDAC cells | J Immunol Res. 2021 Feb 23;2021:5553425 |
| Capan-2 cells | 5 μM, 10 μM, 25 μM | 24 hours | Inhibited migration and invasion of PDAC cells | J Immunol Res. 2021 Feb 23;2021:5553425 |
| Vero E6 cells | 5 μM | 36 hours | Inhibition of ERO1α activity, reducing PEDV-induced ROS generation and significantly suppressing PEDV replication | Vet Res. 2023 Feb 3;54(1):9 |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Hypertrophy induced by thoracic aortic banding (TAB) | Ex vivo heart perfusion | 10 µmol/L | 30 minutes | EN460 pretreatment significantly reduced the incidence of isoproterenol-induced ventricular fibrillation (VF) in TAB hearts, improving arrhythmia propensity | Circ Res. 2022 Mar 4;130(5):711-724 |
| SCID mice | MDAMB231 tumor model | Intraperitoneal injection | 10 mg/kg | Once daily for 6 days | Evaluate the effect of EN460 and I2 on tumor growth, results showed that EN460 and I2 slightly inhibited tumor growth and reduced VEGFA levels | Cell Death Dis. 2025 Feb 17;16(1):105 |
| Zebrafish embryos | Zebrafish embryo model | E3 media | 1-20 μM | 6-30hpf | EN460 at a dose of 10 μM was significantly lethal during early embryonic development. | Bioorg Med Chem Lett. 2017 May 1;27(9):2029-2037 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.17mL 0.43mL 0.22mL |
10.85mL 2.17mL 1.09mL |
21.70mL 4.34mL 2.17mL |
|
| CAS号 | 496807-64-8 |
| 分子式 | C22H12ClF3N2O4 |
| 分子量 | 460.79 |
| SMILES Code | FC(F)(F)C1=NN(C2=CC(C(O)=O)=C(Cl)C=C2)C(/C1=C\C3=CC=C(C4=CC=CC=C4)O3)=O |
| MDL No. | MFCD02951227 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 12 mg/mL(26.04 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1